Picoplatin, Poniard’s lead product candidate, is a new generation platinum agent designed to overcome platinum resistance. The development of molecular signatures of platinum resistance may allow the prediction of clinical response to picoplatin treatment and may improve outcomes for patients with platinum-resistant cancers.
Jerry McMahon, chairman and CEO of Poniard, said: “AltheaDx’s high throughput gene expression platform facilitates the identification of molecular signature of platinum resistance that can guide therapeutic choices.”